KRAS and neoplasm: The clinical benefits of this recognition were first realized in a case of metastatic colorectal cancer, which was successfully treated by adoptive T-cell therapy using ex vivo expanded tumor-derived lymphocytes that specifically recognized KRAS G12D (77).